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Increased glucose metabolism in cancer cells is a phenomenon that has
been known for over 90 years, allowing maximal cell growth through faster
ATP production and redistribution of carbons towards nucleotide, protein
and fatty acid synthesis. Recently, metabolites that can promote tumorige-
neis by altering the epigenome have been identified. These ‘oncometabo-
lites’ include the tricarboxylic acid cycle metabolites succinate and
fumarate, whose levels are elevated in rare tumours with succinate dehy-
drogenase and fumarate hydratase mutations, respectively. 2-Hydroxygluta-
rate is another oncometabolite; it is produced de novo as a result of the
mutation of isocitrate dehydrogenase, and is commonly found in gliomas
and acute myeloid leukaemia. Interestingly, the structural similarity of
these oncometabolites to their precursor metabolite, a-ketoglutarate,
explains the tumorigenic potential of these metabolites, by competitive inhi-
bition of a superfamily of enzymes called the a-ketoglutarate-dependent di-
oxygenases. These enzymes utilize a-ketoglutarate as a cosubstrate, and are
involved in fatty acid metabolism, oxygen sensing, collagen biosynthesis,
and modulation of the epigenome. They include enzymes that are involved
in regulating gene expression via DNA and histone tail demethylation. In
this review, we will focus on the link between metabolism and epigenetics,
and how we may target oncometabolite-induced tumorigenesis in the
future.
Cancer metabolism
It has now been over 90 years since it was first
observed that cancer cells have an altered metabolic
phenotype [1]. In the presence of oxygen, normally dif-
ferentiated cells predominantly utilize the tricarboxylic
acid (TCA) cycle and oxidative phosphorylation to
efficiently produce energy and the metabolites neces-
sary for protein and lipid synthesis. However, in the
presence of hypoxia, this process is altered, and cells
switch to a higher rate of glycolysis and lactate pro-
duction to maintain their energy and metabolic needs.
In cancer cells, glycolysis is maintained at a high rate,
even in the presence of oxygen; this is termed ‘aerobic
glycolysis’. This seems to be counterintuitive, as oxida-
tive phosphorylation is much more efficient at energy
production than glycolysis, producing 34 more ATP
molecules from the same molecule of glucose [2].
Tumour cells, however, are rapidly dividing, and have
a much greater need for anabolism than normally dif-
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ferentiated cells. Rapid glucose metabolism enables
faster ATP production and greater redistribution of
carbons to nucleotide, protein and fatty acid synthesis,
thus maximizing cell growth [3]. [18F]Deoxyglucose
positron emission tomography utilizes this feature of
cancer by allowing visualization of glucose uptake in
patients, and has become an important tool in cancer
diagnosis and the measurement of treatment response
[4]. It has been used to confirm the correlation between
glucose metabolism and cell proliferation rate in some
human tumours [5–7]. Other malignancies, such as
pancreatic cancer, do not show this relationship, prob-
ably because of complex interactions in vivo between
the tumour and the microenvironment [8]. Rapid glu-
cose metabolism can also occur in normal cells, where
there is a need for rapid growth and proliferation,
such during an immune response, during wound heal-
ing, and in utero [9–11]. In cancer cells, however, ‘aer-
obic glycolysis’ can be deregulated, in part because of
genetic mutations, such as in the phosphoinositide
3-kinase–AKT and Myc pathways [3]. In addition,
increased activation in cancer of a specific isoform of
pyruvate kinase, PKM2, has been identified; this,
because of its controlled enzymatic activity, can shift
metabolic flux away from the TCA cycle to other ana-
bolic processes [12]. Recently, other metabolic changes,
driven by mutations in genes related to the TCA cycle,
have indicated an alternative role, that of the ‘oncome-
tabolite’ [13]. In this instance, a particular metabolite
builds up within the cell and contributes to the tumori-
genic process. Mutations in fumarate hydratase (FH)
and succinate dehydrogenase (SDH) subunits follow
the classic Knudson ‘two-hit’ model, with loss of gene
function, and accumulation of the substrates fumarate
and succinate, respectively. Conversely, for isocitrate
dehydrogenase (IDH), a single-allele mutation confers
a gain of function, producing an excess of a new
metabolite, 2-hydroxyglutarate (2HG) [13]. These on-
cometabolites seem to have a common tumorigenic
mechanism, namely the competitive inhibition of a
superfamily of enzymes, the a-ketoglutarate (aKG)-
dependent dioxygenases, which are important modula-
tors of both the oxygen-sensing machinery and the epi-
genome, providing a link between metabolic
dysfunction and altered gene expression in cancer.
Regulation of the epigenome
Over the past 20 years, almost in parallel with the
increasing understanding of cancer metabolomics,
great strides in our knowledge of the epigenome have
been made. This constitutes a range of changes that
occur to DNA expression without altering the DNA
sequence. The chromatin structure is organized in sev-
eral layers that can be modulated to alter gene expres-
sion. One hundred and forty-seven base pairs of DNA
are folded around a histone core, which comprises
eight subunits, i.e. two each of histones H2A, H2B,
H3, and H4, to form a nucleosome. Gene expression
can be modulated epigenetically both at the DNA
nucleotide level through cytosine methylation, and via
chemical modification of histone tails within nucleo-
somes. These processes are essential in normal healthy
tissues to maintain cell lineage and differentiation by
activating and suppressing genes that are vital for cel-
lular functions.
Changes in DNA methylation have long been
known to occur in cancer [14]. This process is modu-
lated by DNA methyltransferases (DNMTs) and 10-
11-translocation methylcytosine dioxygenase (TET),
which, respectively, add and remove methyl groups. In
fact, TET enzymes oxidize (hydroxylate) the methyl
groups, resulting in their removal. Large areas of the
genome of cancer cells are hypomethylated as com-
pared with normal cells, specifically in gene-poor
regions, and are associated with chromatin changes
leading to genomic instability [15]. Conversely, short
regions are hypermethylated, specifically at CpG
islands. These sequences are over 200 bp long, with
over 50% GC content, are usually found near pro-
moter sites, and are associated with gene silencing [16].
A subset of tumours in glioma and colorectal cancer
have been identified with a specific CpG island methyl-
ator phenotype, whereby a large number of such loci
are hypermethylated in a distinctive pattern [17,18].
Gene expression can also be altered by changes in
chromatin structure via chemical modification of
amino acids on histone tails. This can determine the
extent to which DNA is exposed to transcription fac-
tors, and this depends on the type of chemical change,
and the degree and site of modification. A complex
array of modifications can occur, commonly acetyla-
tion and methylation, but also ubiquitination, phos-
phorylation, ADP-ribosylation, and SUMOylation
[19]. Acetylation is catalysed by histone acetyltransfe-
rases (HATs), on lysines, and is associated with
increased gene expression. Conversely, histone deacety-
lases hydroxylate the acetyl group, causing its subse-
quent removal. Histone methylation, however, is more
complex. Amino acids on histone tails, predominantly
lysine, can receive up to three methyl groups by the
action of a variety of histone methyltransferases
(HMTs), with each of these modifications potentially
conferring a different function [20]. Histone modifica-
tion is a dynamic process, so equally important is the
activity of histone demethylases(HDMs), which, similarly
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to TET, catalyse the oxidation of methyl groups,
resulting in their removal. Unlike acetylation, methyla-
tion can be associated with both activation and sup-
pression of genes. Methylation of histone H3 Lys4, for
instance, is associated with gene activation, whereas
methylation of histone H3 Lys9 (H3K9) and methyla-
tion of histone H3 Lys27 (H3K27) are associated with
gene silencing [21]. These epigenetic changes have been
shown to be important in human cancers, with global
changes in histone acetylation and methylation levels
having important prognostic significance in prostate,
colon and non-small-cell lung cancer [22–24].
Drugs have been developed in an attempt to target
these epigenetic hallmarks of cancer. DNMTs were the
first to be targeted successfully. Decitabine and azaciti-
dine were developed > 50 years ago, but were limited
to the treatment of myelodysplastic syndromes, owing
to toxic side effects at high doses [25]. The only other
drugs used in clinical practice are vorinostat and romi-
depsin, which inhibit histone deacetylases. Both drugs
are used in the treatment of T-cell lymphoma, but, dis-
appointingly, they have also failed to show clinical effi-
cacy in other tumour types, owing to toxicity [26]. To
date, other potential targets, such as HMTs, have not
provided any meaningful clinical results. This difficulty
in drug development may be attributable to the broad
activity of these enzymes, which often also act on non-
nuclear proteins [27]. Targeting the metabolic causes
of these epigenetic changes may therefore have greater
clinical potential.
The metabolic mechanism of
epigenetic change
Metabolism and epigenetics are linked through the pro-
cesses of methyl and acetyl transfer, utilizing S-adenyl-
methionine (SAM) and acetyl-coenzyme A as substrates
respectively (Fig. 1). SAM is generated from the cou-
pled folate and methionine cycles, collectively called
one-carbon metabolism. This is also essential for the
synthesis of nucleotides, protein, lipids, and glutathi-
one, which maintains the redox state of the cell. For this
reason, it is often overactive in cancer [28], and is the
reason why folate antagonists, such as methotrexate
and pemetrexate, have proved to be successful in the
clinic. Serine, glycine, methionine and folic acid are
important sources for one-carbon metabolism, and can
be taken up by the cell. However, serine, glycine and
methionine can be synthesized de novo in the cell, which
helps to maintain one-carbon metabolism when nutri-
ents are scarce. Serine, which can be synthesized from
3-phosphoglycerate, an intermediate in glycolysis,
donates a carbon to the folate cycle while producing
glycine, and converting tetrahydrofolate to methyltetra-
hydrofolate (mTHF). Glycine in turn, through the gly-
cine cleavage system, can also provide one carbon, to
produce mTHF. mTHF forms the link to the methio-
nine cycle by providing the methyl group for betaine
hydroxymethyltransferase to catalyse the reaction of
homocysteine to methionine. Methionine can, in turn,
be utilized in protein and lipid synthesis or adenylated
to SAM, the major methyl donor in the cell. SAM is
then utilized by DNA and HMTs to methylate amino
acids on DNA and histone tails, respectively.
Acetylation of histones is dependent on the acetyl
donor, acetyl-coenzyme A. Acetyl-coenzyme A is an
important link between glycolysis and the TCA cycle
in the mitochondria, and its formation is catalysed by
pyruvate dehydrogenase. In the cytoplasm and
nucleus, however, acetyl-coenzyme A production is
dependent on two different enzymes: ATP-citrate lyase
(ACLY) and acetyl-coenzyme A synthetase short-chain
family member 2 (ACSS2) (Fig. 1) [29]. ACLY pro-
duces acetyl-coenzyme A from citrate, whereas ACSS2
ligates acetate to CoA. Acetyl-coenzyme A then acts
as the acetyl donor for lysine acetylation on histone
tails by HAT. Whereas ACLY derives acetyl-coenzyme
A from the TCA cycle, ACSS2 is important as a scav-
enger of CoA from histone, protein and lipid deacety-
lation reactions. Interestingly, it may also utilize
exogenous acetate, especially during hypoxia, as a
source of acetyl-coenzyme A [30,31].
Oncometabolites and their effect on
the epigenome
Several mutations in metabolic genes that lead to can-
cer formation have been identified over the last
15 years. These can promote epigenetic changes
through a common mechanism, the accumulation of
an ‘oncometabolite’, that acts as a competitive inhibi-
tor of aKG-dependent dioxygenases, an ever-expand-
ing superfamily of > 60 enzymes. Dioxygenases are
involved in fatty acid metabolism, oxygen sensing, col-
lagen biosynthesis, and modulation of the epigenome
[32]. Chemically, they all share a common requirement
for oxygen and aKG as cosubstrates. Hydroxylation
of the primary substrate occurs in conjunction with
the oxidative decarboxylation of aKG to generate suc-
cinate and carbon dioxide (Fig. 2).
The first such effect was demonstrated for the loss
of function of SDH in cancer. SDH loss was initially
discovered in familial paraganglioma [33], but also
occurs as a result of spontaneous somatic mutations
[34]. These tumours are of neuroendocrine origin and
most commonly affect the carotid body, but can occur
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anywhere in the sympathetic and parasympathetic
chain, as well as in the catecholamine-secreting chro-
maffin cells in the adrenal gland; in this case, the
tumour is called phaechromocytoma. SDH is a TCA
cycle enzyme, and also complex II of the electron
transport chain. It oxidizes succinate to fumarate, with
the transfer of an electron to ubiquinone contributing
to ATP production. The enzyme consists of four su-
bunits, each of which can be mutated, causing a loss
of function [33,35–37].
FH catalyses the next reaction in the TCA cycle: the
hydration of fumarate to malate. Similarly to SDH,
loss of function of FH was also identified in a familial
syndrome (hereditary leiomyomatosis and renal cell
cancer) resulting in smooth muscle tumours called leio-
myomas and aggressive renal cell carcinomas [38].
Furthermore, FH loss have subsequently been identi-
fied, like SDH mutations, in paragangliomas and
phaechromocytomas [39]. In FH-deficient and SDH-
deficient tumours, there is the respective accumulation
Fig. 1. Methyl and acetyl transfer pathways. The blue pathway depicts one-carbon metabolism and its generation of SAM, which provides a
methyl group for histone and DNA methylation. Imported folate is reduced to tetrahydrofolate (THF) and subsequently methylated to mTHF
by the conversion of serine to glycine and the glycine cleavage system. The folate cycle is coupled to the methionine cycle by mTHF,
donating a carbon to homocysteine, converting it to methionine. Adenylation of methionine produces SAM, which acts as a cosubstrate for
DNMT and HMT, allowing transfer of its methyl group to DNA and histone tails respectively. The red pathway depicts acetyl transfer from
acetyl-coenzyme A. Acetyl-coenzyme A, which is derived from pyruvate, links glycolysis to the TCA cycle, but is confined to the
mitochondria. In the cytoplasm and nucleus, acetyl-coenzyme A has to be derived by two alternative methods: first by ACLY, which utilizes
citrate from the mitochondrial TCA cycle, and second by ACSS2, which ligates acetate to CoA. Acetyl-coenzyme A can then be utilized
as a cosubstrate by HAT, allowing transfer of the acetyl group to lysines on histone tails. 3-PG, 3-phosphoglyceric acid; SAH,
S-adenosylhomocysteine.
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of fumarate or succinate, which have a common effect
by competitively inhibiting aKG-dependent dioxygen-
ases [40]. It seems likely that succinate and fumarate,
which are structurally similar, inhibit these enzymes
through product inhibition, as the effects of both
metabolites can be reversed by the addition of excess
aKG in vitro and in vivo [41] (Fig. 3).
IDH is another TCA-cycle related enzyme that has
been implicated in tumorigenesis. On genomic screen-
ing, it was identified being commonly mutated in glio-
mas and in acute myeloid leukaemia (AML) [42–44].
Interestingly, IDH mutations are associated with a bet-
ter prognosis in glioma, but a poorer prognosis in AML
[45]. Subsequently, mutations have also been identified
in other rare types of solid tumours, such as cholangio-
carcinoma and chondrosarcoma [46,47]. IDH exists as
three isoforms (IDH1, IDH2, and IDH3), with IDH1
being present in the cytoplasm and IDH2 and IDH3 in
the mitochondria. IDH1 and IDH2 convert isocitrate to
aKG by oxidative decarboxylation, with the production
of NADPH from NADP+. IDH3 is structurally differ-
ent from the other two isoforms, and utilizes NAD+ to
produce aKG and NADH. It has not been found to be
mutated in any cancer to date. The site of the mutation
in IDH1 and IDH2 is at an equivalent arginine that is
important to the active site for isocitrate binding [13].
The mutation results in increased affinity aKG instead,
and the mutated enzyme utilizes NADPH in a partially
reversed reaction to produce a new metabolite, 2HG
[13]. 2HG is structurally very similar to aKG and gluta-
mate, the only difference being the presence of a hydro-
xyl group instead of a ketone or amine group,
respectively (Fig. 3). It is this similarity that results in
the competitive inhibition of aKG-dependent dioxygen-
ases by 2HG, as it occupies the same binding site as
aKG [48]. Interestingly, the IDH1/IDH2 mutation is
associated with a decrease in the level of aKG, poten-
tially enhancing the inhibitory effect of 2HG on dioxy-
genases [49,50].
A subgroup of aKG-dependent dioxygenases impli-
cated in tumorigenesis are the prolyl hydroxylases
(PHDs), which play an important role in the degrada-
tion of hypoxia-inducible factor (HIF) in normoxic con-
ditions. HIF activates a range of genes in response to
low oxygen, to increase glycolysis and angiogenesis. In
Fig. 2. aKG-dependent dioxygenases. This superfamily of enzymes
uses oxygen and aKG as cosubstrates, resulting in the
hydroxylation of the primary substrate and the decarboxylation of
aKG, producing succinate and CO2. These enzymes can be
inhibited by elevated levels of 2HG, succinate, or fumarate. This
occurs by competition with the cosubstrate, aKG, and/or by















Fig. 3. Metabolic structure of oncometabolites: Succinate, fumarate and 2HG are closely linked, both structurally and metabolically, to aKG.
Succinate and fumarate differ from aKG only by the presence of a hydroxyl group on C2 and the loss of C1. In addition, succinate and
fumarate differ only by the presence of an ethylenic bond, which may explain their similar tumorigenic effects. 2HG differs from aKG and
glutamate only by the presence of a hydroxyl group instead of a ketone group or amine group, respectively. This explains how 2HG can
competitively inhibit aKG by occupying the same enzymatic binding site.
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the presence of oxygen, PHDs hydroxylate prolyl
groups on HIF, allowing it to bind to the von Hippel–
Lindau protein, which tags HIF for ubiquitylation and
degradation in the proteasome [51]. FH and SDH muta-
tions cause a ‘pseudohypoxic’ phenotype through the
inhibition of PHDs, which stabilizes HIF. This pro-
motes a hypoxic response even in the presence of oxy-
gen, causing increased glycolysis and angiogenesis
[41,52]. The effect of 2HG on PHDs is less clear, with
conflicting evidence of both inhibitory and activating
effects [48,53–55]. This indicates variations between on-
cometabolites in their sensitivity to different members of
the aKG-dependent dioxygenase family of enzymes.
IDH, FH and SDH mutations are associated with
changes in DNA and histone methylation. A subset of
gliomas has been identified that has a distinct pattern
of CpG island hypermethylation [17], which has been
replicated in mutant IDH1-overexpressing immortal-
ized astrocytes, and a single-copy IDH1 mutant
knock-in colorectal cell line [56,57]. IDH mutations in
cholangiocarcinoma also replicate this hypermethyla-
tion pattern [58]. This is also likely to extend to SDH
mutations, with similar patterns of DNA methylation
being observed in mouse-derived SDH-deficient chro-
maffin cells [59]. The underlying mechanism for these
changes seems to be inhibition of TET, an aKG-
dependent dioxygenase, which exists in three isoforms
(TET1–TET3). They hydroxylate 5-methylcytosine to
5-hydroxymethylcytosine (5-hmC), allowing subse-
quent DNA demethylation. In human glioma tissue
samples, 5-hmC levels are markedly reduced in IDH
mutant as compared with IDH wild-type tumours [48].
In cell culture, this reduction in 5-hmC levels has been
replicated by overexpressing mutant IDH1/IDH2 in
numerous cell lines, including glioma cells, immortal-
ized astrocytes, and myeloblasts [56,60]. The same
effect has also been observed in FH and SDH mutant
cell models [40]. Interestingly, in human AML sam-
ples, mutations in TET2 were found to be mutually
exclusive to mutations in IDH, and to produce similar
DNA methylation patterns to those in IDH mutant
AML [60]. Further genomic analysis of IDH1/IDH2
mutant AML revealed increased methylation of pro-
moter sites of genes associated with myeloid differenti-
ation, producing a more stem-like phenotype [60].
Overexpression of IDH1, or exposure to exogenous
cell-permeable 2HG, was able to promote cytokine
independence and block differentiation in a leukaemic
cell line. This could be replicated by knockdown of
TET2, providing a potential link between 2HG, TET
inhibition, and tumorigenesis [61].
The jumunji-C HDMs are a subgroup of HDMs
that are members of the a-KG-dependent dioxygenase
family [32]. They initiate the first step in the removal
of methyl groups by hydroxylation, causing an
increase or decrease in gene transcription, depending
on the histone methylation site. Jumunji-C HDMs are
very sensitive to high levels of fumarate, succinate, and
2HG [62]. In the case of the IDH1/IDH2 mutation,
increases in histone methylation have been observed in
human glioma samples for H3K9 and H3K27, both of
which are gene repressive marks [48,63]. Interestingly,
the IDH1 mutation was strongly correlated with the
level of trimethylated H3K9 (H3K9me3) in oligoden-
drogliomas but not in astrocytomas, which are two
different subtypes of glioma [64]. This implies that
there is a differential effect of 2HG on different
tumours even in the same tissue type. Murine 3T3-L1
cells, which can be differentiated into adipocytes, were
used to prove a link between the repressive histone
methylation marks H3K9me3 and trimethylated
H3K27 (H3K27me3), and cellular differentiation.
Overexpression of mutant IDH1 was associated with
impaired adipogenesis resulting from increases in both
H3K9me3 and H3K27me3 at promoter sites for tran-
scription factors responsible for adipocyte differentia-
tion. Similar changes in histone methylation markers,
and impaired differentiation, were also seen in IDH1-
overexpressing primary murine neurospheres [63].
Increases in H3K27me3 and H3K9me3 levels have also
been observed in SDH and FH mutant tumours and
cell models [40,59]. Interestingly, increased levels of
H3K9me3 occur prior to increases in DNA methyla-
tion when mutant IDH1 is introduced into immortal-
ized astrocytes [63]. These histone methylation changes
may therefore account for some of the changes in
DNA methylation patterns [65].
Future therapies
There is now increasing evidence that mutations in
metabolic enzymes are, in part, responsible for the epi-
genetic changes in some cancers. At least in AML,
there is good evidence to suggest that the IDH1 muta-
tion alone may be sufficient to induce leuko-neogenesis
by inhibiting genes responsible for cell differentiation
through DNA hypermethylation [61]. For other
tumours, this is less clear, but, at least in glioma, the
IDH mutation seems to be an early event that is main-
tained throughout tumour progression [42]. It is also
becoming evident that the presence of oncometabolites
in tumours is not confined to malignancies with TCA
gene mutations. Elevated levels of 2HG, driven by
myc activation, have been identified in breast cancer,
resulting in DNA hypermethylation [66]. Interestingly,
3-phosphoglycerate dehydrogenase, which is the
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enzyme responsible for the first step in serine biosyn-
thesis from the glycolytic intermediate 3-phosphoglyc-
erate, has recently been shown to convert aKG to
2HG by utilizing NADH [67]. This provides a possible
link between increased myc-driven glycolysis and 2HG
production in some breast cancers. It seems likely that
other tumours may also be affected, and new oncome-
tabolites may be identified in the future. In fact, an
in silico systems approach using 1700 genomes has
already been used to identify potential new oncome-
tabolites in a range of tumours [68].
The discovery of metabolic enzymes that can alter
the epigenome has opened up a new, exciting area for
drug development. In only 5 years, IDH1 and IDH2
small-molecule inhibitors have been developed that are
now entering clinical trials. AGI-5198, an IDH1 inhib-
itor, was tested in a heterozygous IDH1 mutant gli-
oma cell line (TS603). It was able to reverse H3K9
trimethylation, promote cellular differentiation, and
delay growth, although, interestingly, it had no effect
on DNA methylation [69]. Similarly, AGI-6780, a spe-
cific inhibitor of mutant IDH2, induced leukaemic cell
differentiation in primary human samples ex vivo [70].
Further investigation using a mutant IDH2-overex-
pressing leukaemic cell line showed reversal of both
DNA and histone hypermethylation, inducing cell dif-
ferentiation. Interestingly, histone methylation is rap-
idly reversed within days, whereas DNA methylation
progressively changes over a period of weeks [71]. This
may account for the lack of change in DNA hyperme-
thylation seen with AGI-5198.
It will be interesting to determine whether these
new drugs are equally efficacious in different types of
IDH-mutated tumour. In glioma, the presence of an
IDH1 mutation is actually associated with better
prognosis than that of wild-type tumours. These
tumours grow more slowly in vitro and in vivo [72].
The concern in glioma is that inhibiting 2HG pro-
duction may potentiate tumour growth. Reduced
expression of branched-chain amino acid transferase
1 (BCAT1) in IDH1-mutated gliomas has been
shown, in part, to be caused by hypermethylation of
the BCAT1 promoter region. When BCAT1 is over-
expressed in IDH1-mutant immortalized human as-
trocytes, some of the loss in cell proliferation is
recovered [73]. This raises the concern that inhibition
of the mutant IDH enzyme in glioma may increase
cell proliferation, and we may need to focus on spe-
cific downstream pathways affected by 2HG. This is
in direct contrast to AML, in which IDH mutations
are associated with a worse prognosis and more
aggressive disease, and in which mutant IDH inhibi-
tors may prove more beneficial.
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